0000899243-22-014804.txt : 20220414 0000899243-22-014804.hdr.sgml : 20220414 20220414163505 ACCESSION NUMBER: 0000899243-22-014804 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220412 FILED AS OF DATE: 20220414 DATE AS OF CHANGE: 20220414 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Yuchun CENTRAL INDEX KEY: 0001334365 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 22827725 MAIL ADDRESS: STREET 1: 170 TRACER LA. CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-12 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001334365 Lee Yuchun C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 Common Stock 2022-04-12 4 M 0 2000 81.54 A 3875 D Common Stock 2022-04-12 4 S 0 200 279.22 D 3675 D Common Stock 2022-04-12 4 S 0 1182 280.61 D 2493 D Common Stock 2022-04-12 4 S 0 318 281.70 D 2175 D Common Stock 2022-04-12 4 S 0 300 283.15 D 1875 D Common Stock 2022-04-13 4 M 0 2000 81.54 A 3875 D Common Stock 2022-04-13 4 S 0 18 281.49 D 3857 D Common Stock 2022-04-13 4 S 0 300 283.73 D 3557 D Common Stock 2022-04-13 4 S 0 228 284.90 D 3329 D Common Stock 2022-04-13 4 S 0 300 286.24 D 3029 D Common Stock 2022-04-13 4 S 0 200 287.42 D 2829 D Common Stock 2022-04-13 4 S 0 400 288.55 D 2429 D Common Stock 2022-04-13 4 S 0 200 290.17 D 2229 D Common Stock 2022-04-13 4 S 0 354 291.12 D 1875 D Stock Option (Right to Buy) 81.54 2022-04-12 4 M 0 2000 0.00 D 2023-05-31 Common Stock 2000 6000 D Stock Option (Right to Buy) 81.54 2022-04-13 4 M 0 2000 0.00 D 2023-05-31 Common Stock 2000 4000 D Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $279.22 (range $279.14 to $279.30). Open market sales reported on this line occurred at a weighted average price of $280.61 (range $280.24 to $281.19). Open market sales reported on this line occurred at a weighted average price of $281.70 (range $281.45 to $281.98). Open market sales reported on this line occurred at a weighted average price of $283.15 (range $282.73 to $283.57). Open market sales reported on this line occurred at a weighted average price of $283.73 (range $283.30 to $284.10). Open market sales reported on this line occurred at a weighted average price of $284.90 (range $284.66 to $284.95). Open market sales reported on this line occurred at a weighted average price of $286.24 (range $285.99 to $286.60). Open market sales reported on this line occurred at a weighted average price of $287.42 (range $287.02 to $287.83). Open market sales reported on this line occurred at a weighted average price of $288.55 (range $288.23 to $289.11). Open market sales reported on this line occurred at a weighted average price of $290.17 (range $289.72 to $290.62). Open market sales reported on this line occurred at a weighted average price of $291.12 (range $290.80 to $291.42). Fully vested. /s/ Sabrina Yohai, Attorney-in-Fact 2022-04-14